Following up to the original article - Globus continues to eat orthopedics with fantastic financial numbers including 25% revenue growth Y/Y.
Look at this performance by the numbers below.
Globus Medical (NYSE: GMED) delivered strong year-over-year growth in 2025, with acceleration in Q4, driven by solid base-business performance, the Nevro acquisition (which contributed ~$99.7 million in Q4 sales), and ongoing benefits from the earlier NuVasive integration. The company highlighted double-digit sales/earnings growth, margin expansion, and operating leverage. Below is a clear YoY summary directly from the Feb. 24, 2026 earnings release (all % changes are as-reported unless noted).Full-Year 2025 vs. 2024
Worldwide net sales: $2,938.9 million+16.7% (+16.2% constant currency)(Implied 2024: ~$2,518 million)
Base business net sales (excluding Nevro): $2,645.3 million+5.0% (+4.3% constant currency)
U.S. net sales: +18.4%
International net sales: +10.0% as reported (+7.8% constant currency)
GAAP net income: $537.9 millionGAAP diluted EPS: $3.92 (+425.4%) (Implied 2024 EPS: $0.75)
Non-GAAP diluted EPS: $3.98 (+30.8%) (Implied 2024: $3.04)
Q4 2025 vs. Q4 2024
Worldwide net sales: $826.4...
